Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981137 | 0.88 | PAOX (0.39) | TSHRGNAI3GNAO1GNAI1USP2 | |
| SCHEMBL20227876 | 0.86 | USP2 (0.36) | GNAI3GNAO1GNAI1USP2KDM1A | |
| SCHEMBL20850661 | 0.86 | HRH3 (0.44) | TSHRGNAI3GNAO1GNAI1MAPK1 | |
| SCHEMBL23948364 | 0.85 | KEAP1 (0.42) | TSHRGNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL24723682 | 0.84 | HRH3 (0.48) | TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL24723810 | 0.84 | HRH3 (0.48) | TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL11932497 | 0.81 | GBA1 (0.41) | GNAI3GNAO1GNAI1KDM1AMAPK1 | |
| SCHEMBL26940040 | 0.81 | CXCR4 (0.44) | TSHRGNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL19407025 | 0.81 | KEAP1 (0.47) | TSHRUSP2MAPK1KDM4EALDH1A1 | |
| SCHEMBL24975389 | 0.80 | GNAI3 (0.37) | GNAI3GNAO1GNAI1USP2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |